Focus Partners Wealth Acquires 686,009 Shares of Thermo Fisher Scientific Inc. $TMO

by · The Markets Daily

Focus Partners Wealth raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 265.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 944,756 shares of the medical research company’s stock after acquiring an additional 686,009 shares during the quarter. Focus Partners Wealth’s holdings in Thermo Fisher Scientific were worth $547,434,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Assetmark Inc. raised its holdings in Thermo Fisher Scientific by 22.9% in the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock worth $21,819,000 after purchasing an additional 7,023 shares during the period. Mackenzie Financial Corp raised its holdings in Thermo Fisher Scientific by 29.4% in the third quarter. Mackenzie Financial Corp now owns 276,545 shares of the medical research company’s stock worth $134,130,000 after purchasing an additional 62,790 shares during the period. NEOS Investment Management LLC raised its holdings in Thermo Fisher Scientific by 28.6% in the third quarter. NEOS Investment Management LLC now owns 51,364 shares of the medical research company’s stock worth $24,913,000 after purchasing an additional 11,415 shares during the period. Factory Mutual Insurance Co. raised its holdings in Thermo Fisher Scientific by 2.6% in the third quarter. Factory Mutual Insurance Co. now owns 98,935 shares of the medical research company’s stock worth $47,985,000 after purchasing an additional 2,500 shares during the period. Finally, North Dakota State Investment Board acquired a new stake in Thermo Fisher Scientific in the fourth quarter worth $7,505,000. 89.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on TMO shares. Barclays cut their target price on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. Wolfe Research started coverage on shares of Thermo Fisher Scientific in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $535.00 target price on the stock. Morgan Stanley restated an “overweight” rating and set a $620.00 price objective on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Finally, Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $608.95.

View Our Latest Research Report on TMO

Insiders Place Their Bets

In related news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Trading Down 1.4%

Shares of NYSE:TMO opened at $468.80 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The company’s fifty day simple moving average is $479.14 and its 200 day simple moving average is $527.68. The firm has a market cap of $174.22 billion, a price-to-earnings ratio of 25.77, a PEG ratio of 2.08 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. During the same period last year, the business posted $5.15 earnings per share. The firm’s quarterly revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 24.85 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Featured Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).